Market Tracker

08/25 5:16pm ET

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

129.17
Delayed Data
As of 3:59pm ET
 -2.95 / -2.23%
Today’s Change
110.56
Today|||52-Week Range
193.45
-32.28%
Year-to-Date
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug 24 / Zacks.com - Paid Partner Content
Spiros 'Sig' Segalas' Capital Appreciation Fund 2nd Quarter Commentary
Aug 18 / GuruFocus News - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for August 15th
Aug 15 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
Alnylam Pharmaceuticals, Inc. Cranks Out the Data
Aug 12 / MotleyFool.com - Paid Partner Content
Spiros Segalas on Alexion Pharmaceuticals
Aug 18 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close132.12
Today’s open133.43
Day’s range127.46 - 133.43
Volume1,695,228
Average volume (3 months)1,788,173
Market cap$29.6B
Dividend yield--
Data as of 3:59pm ET, 08/25/2016

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)-6.51%
Earnings growth (next 5 years)+24.20%
Revenue growth (last year)+12.25%
P/E ratio430.6
Price/Sales16.57
Price/Book3.61

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc-0.16-0.32%
VRTXVertex Pharmaceutica...-0.33-0.34%
MYLMylan NV-0.30-0.70%
REGNRegeneron Pharmaceut...-5.00-1.23%
Data as of 4:00pm ET, 08/25/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)$1.19
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David L. Hallal
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
Cheshire, Connecticut

Forecasts